Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 5Phase 1 4Phase NA 3Phase 3 2

Status

Recruiting 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5

Conditions

Breast Neoplasms 102Carcinoma, Non-Small-Cell Lung 93Multiple Myeloma 80Prostatic Neoplasms 74Colorectal Neoplasms 59Neoplasms 57Leukemia, Myeloid, Acute 56Lymphoma 48Squamous Cell Carcinoma of Head and Neck 43Lung Neoplasms 39Ovarian Neoplasms 38Melanoma 38Neoplasm Metastasis 36Pancreatic Neoplasms 35Lymphoma, Non-Hodgkin 35Carcinoma, Hepatocellular 34Lymphoma, Large B-Cell, Diffuse 33Sarcoma 31Head and Neck Neoplasms 31Urinary Bladder Neoplasms 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Carcinoma, Renal Cell 29Leukemia, Lymphocytic, Chronic, B-Cell 28Hodgkin Disease 28Endometrial Neoplasms 28Triple Negative Breast Neoplasms 27Myelodysplastic Syndromes 26Recurrence 25Hematologic Neoplasms 25Glioma 25

Interventions

mirvetuximab soravtansine 1irinotecan sucrosofate 1Tinzaparin 1Paclitaxel 1Losartan 1Clarithromycin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Ovarian Epithelial × 30 days × Clear all
NCT07341100 2026-06-01

Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Active not recruiting
20 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT06890338 2026-05-29

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

AbbVie

Phase 2 Recruiting
140 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT07591831 2026-05-18

Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
30 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05284552 2026-05-11

Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer

University Hospital, Linkoeping

Phase 2 Recruiting
40 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT07265739 2026-05-06

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

Massachusetts General Hospital

Phase 2 Not yet recruiting
27 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡